The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors

BACKGROUND: Contemporary gastroenteropancreatic neuroendocrine tumor (GEPNET) management guidelines recommend routine use of functional imaging preoperatively, but there are few data highlighting trends in functional imaging adoption. This report reviews 24 years of neuroendocrine tumor (NET) experience to describe changes in rates of preoperative functional imaging use and highlights performance differences between functional imaging types in small bowel NETs (SBNET) and pancreatic NETs (PNETs). METHODS: A retrospective single-institution study from 2000 to 2023 identified patients with SBNETs and PNETs treated with surgical resection, cytoreduction, or both who underwent preoperative functional imaging. The primary measurements were frequency of functional imaging use and location of metastases identified on preoperative imaging. RESULTS: The study included 392 SBNET and 208 PNET patients. Preoperative functional imaging was performed for 248 (63.3%) SBNET patients (158 somatostatin receptor [SSTR] positron emission tomography [PET] and 90 Octreoscan) and 113 (54.3%) PNET patients (47 SSTR PET and 66 Octreoscan). There was a significant positive trend over time in functional imaging use in SBNET patients, with an approximate 2.5% yearly increase (p < 0.01) but no significant change in PNET patients during the course of the study (p = 0.82). At presentation, 82.3% (204/248) of the SBNET patients and 54.9% (62/113) of the PNET patients had metastatic disease. Compared with Octreoscan, SSTR PET more frequently identified bone and retroperitoneal nodal metastases. CONCLUSION: Rates of functional imaging use in SBNET patients but not in PNET patients increased significantly during the last 24 years. Patients with SBNETs and PNETs frequently presented with metastatic disease, and SSTR-based functional imaging was extremely helpful in identifying distant disease, intra-operative planning, and further management.

Authors

Institutions

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-10-16
DOI
https://doi.org/10.1245/s10434-026-20735-9
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors

Joseph Stephen Dillon, Jeremy Chang, Yusuf Menda, Andrew M. Bellizzi et al.
Annals of Surgical Oncology
Neuroendocrine Tumor Research Advances
article

The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors

Joseph Stephen Dillon, Jeremy Chang, Yusuf Menda, Andrew M. Bellizzi, James R. Howe, Luis C. Borbon, Carlos H.F. Chan, Po Hien Ear, Brandon Toliver, Scott K. Sherman
article en

Abstract

BACKGROUND: Contemporary gastroenteropancreatic neuroendocrine tumor (GEPNET) management guidelines recommend routine use of functional imaging preoperatively, but there are few data highlighting trends in functional imaging adoption. This report reviews 24 years of neuroendocrine tumor (NET) experience to describe changes in rates of preoperative functional imaging use and highlights performance differences between functional imaging types in small bowel NETs (SBNET) and pancreatic NETs (PNETs). METHODS: A retrospective single-institution study from 2000 to 2023 identified patients with SBNETs and PNETs treated with surgical resection, cytoreduction, or both who underwent preoperative functional imaging. The primary measurements were frequency of functional imaging use and location of metastases identified on preoperative imaging. RESULTS: The study included 392 SBNET and 208 PNET patients. Preoperative functional imaging was performed for 248 (63.3%) SBNET patients (158 somatostatin receptor [SSTR] positron emission tomography [PET] and 90 Octreoscan) and 113 (54.3%) PNET patients (47 SSTR PET and 66 Octreoscan). There was a significant positive trend over time in functional imaging use in SBNET patients, with an approximate 2.5% yearly increase (p < 0.01) but no significant change in PNET patients during the course of the study (p = 0.82). At presentation, 82.3% (204/248) of the SBNET patients and 54.9% (62/113) of the PNET patients had metastatic disease. Compared with Octreoscan, SSTR PET more frequently identified bone and retroperitoneal nodal metastases. CONCLUSION: Rates of functional imaging use in SBNET patients but not in PNET patients increased significantly during the last 24 years. Patients with SBNETs and PNETs frequently presented with metastatic disease, and SSTR-based functional imaging was extremely helpful in identifying distant disease, intra-operative planning, and further management.

Annals of Surgical Oncology
University of Iowa (US), University of Iowa Health Care (US)
National Institutes of Health
Good health and well-being
Openalex Percentile: Top 12%
Neuroendocrine Tumor Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.